[1] RinellaM E, Lazarus J V, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol, 2023,79(6):1542-1556.
[2] KanwalF, Shubrook J H, Adams L A, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease[J]. Gastroenterology, 2021,161(5):1657-1669.
[3] MarekG W, Malhi H. MetALD: Does it require a different therapeutic option?[J]. Hepatology, 2024.
[4] O′SheaR S, Dasarathy S, McCullough A J. Alcoholic liver disease[J]. Hepatology, 2010,51(1):307-328.
[5] StickelF, Lutz P, Buch S, et al. Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers[J]. Hepatology, 2020,72(1):88-102.
[6] Aron-WisnewskyJ, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders[J]. Nat Rev Gastroenterol Hepatol, 2020,17(5):279-297.
[7] BajajJ S, Gavis E A, Fagan A, et al. A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder[J]. Hepatology, 2021,73(5):1688-1700.
[8] KranzlerH R, Soyka M. Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review[J]. JAMA, 2018,320(8):815-824.
[9] YounossiZ M, Corey K E, Lim J K. AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review[J]. Gastroenterology, 2021,160(3):912-918.
[10] PattonH, Heimbach J, McCullough A. AGA Clinical Practice Update on Bariatric Surgery in Cirrhosis: Expert Review[J]. Clin Gastroenterol Hepatol, 2021,19(3):436-445.
[11] LeggioL, Hendershot C S, Farokhnia M, et al. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders[J]. Nat Med, 2023,29(12):2993-2995.
[12] MarxN, Husain M, Lehrke M, et al. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes[J]. Circulation, 2022,146(24):1882-1894.
[13] DanknerR, Murad H, Agay N, et al. Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes[J]. JAMA Netw Open, 2024,7(1):e2350408.
[14] WangL, Wang W, Kaelber D C, et al. GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity[J]. JAMA Oncol, 2024,10(2):256-258.
[15] HarrisonS A, Bedossa P, Guy C D, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis[J]. N Engl J Med, 2024,390(6):497-509.
[16] FrancqueS M, Bedossa P, Ratziu V, et al. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH[J]. N Engl J Med, 2021,385(17):1547-1558.
[17] HarrisonS A, Ruane P J, Freilich B, et al. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis[J]. JHEP Rep, 2023,5(1):100563.
[18] DesaiB N, Singhal G, Watanabe M, et al. Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury[J]. Mol Metab, 2017,6(11):1395-1406.
[19] ScheenA J. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications[J]. Diabetes Metab, 2019,45(3):213-223.
[20] JinZ, Yuan Y, Zheng C, et al. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials[J]. J Diabetes Complications, 2023,37(8):108558. |
